Evidence map›Paper›PMID 39048916›Full record

ArticleJournal of cellular and molecular medicine2024

Generation of B7-H3 isoform regulated by ANXA2/NSUN2/YBX1 axis in human glioma.

Yifen Shen, Chunfang Ma, Xiangxiang Li, Xiaosong Li, Yuxiang Wu, Tao Yang, Yanping Hu, Chao Liu, Hao Shen, Pin Guo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yifen ShenCentral Laboratory, Suzhou Bay Clinical College, Xuzhou Medical University, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.
Chunfang MaClinical Laboratory, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.
Xiangxiang LiClinical Laboratory, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.
Xiaosong LiDepartment of Anorectal Surgery, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.
Yuxiang WuDepartment of Pathology, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.
Tao YangDepartment of Medical Cosmetology, Suzhou Ninth People's Hospital, Soochow University, Suzhou, Jiangsu, China.
Yanping HuDepartment of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China.
Chao LiuCentral Laboratory, Suzhou Bay Clinical College, Xuzhou Medical University, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.ORCID 0009-0003-8889-4685
Hao ShenClinical Laboratory, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.
Pin GuoDepartment of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yihang ShenCentral Laboratory, Suzhou Bay Clinical College, Xuzhou Medical University, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China.ORCID 0000-0002-2923-1641

Funding

General Program of Natural Science Foundation of Shandong Province ZR2020MH261Gusu Health Talent Training Project GSWS2019087Jiangsu Province High-level Innovation and Entrepreneurship Talent Plan JSSCBS20222022Program of Developing Public Health through Science and Education of Wujiang District, Suzhou wwk202306Project of Suzhou Ninth People's Hospital YK202226Project of Suzhou Ninth People's Hospital YK202425Science and Technology Planning Fund of Affiliated Hospital of Xuzhou Medical University XYFY202219Science and Technology Planning Fund of Affiliated Hospital of Xuzhou Medical University XYFY202306Science and Technology Planning Fund of Affiliated Hospital of Xuzhou Medical University XYFY202307Science and Technology Planning Project SKYD2022023the People's Livelihood Science and Technology of Suzhou SYSD2020043Youth Program of Developing Public Health through Science and Education of Suzhou KJXW2023081
6 · The paper itself

Abstract

In recent years, in the development of emerging immunotherapy, B7-H3 is also termed as CD276 and has become a novel chimeric antigen receptor (CAR)-T target against glioma and other tumours, and aroused extensive attention. However, B7-H3 has three isoforms (2, 3 and 4Ig) with the controversial expression and elusive function in tumour especially glioma. The current study mainly focuses on the regulatory factors and related mechanisms of generation of different B7-H3 isoforms. First, we have determined that 2Ig is dominant in glioma with high malignancy, and 4Ig is widely expressed, whereas 3Ig shows negative expression in all glioma. Next, we have further found that RNA binding protein annexin A2 (ANXA2) is essential for B7-H3 isoform maintenance, but fail to determine the choice of 4Ig or 2Ig. RNA methyltransferase NOP2/Sun RNA methyltransferase 2 (NSUN2) and 5-methylcytosine reader Y-box binding protein 1 (YBX1) facilitate the production of 2Ig. Our findings have uncovered a series of factors (ANXA2/NSUN2/YBX1) that can determine the alternative generation of different isoforms of B7-H3 in glioma. Our result aims to help peers gain a clearer understanding of the expression and regulatory mechanisms of B7H3 in tumour patients, and to provide better strategies for designing B7H3 as a target in immunotherapy.

Indexed as

Annexin A2B7 AntigensGene Expression Regulation, NeoplasticGliomaProtein IsoformsBrain NeoplasmsCell Line, TumorHumansAnnexin A2ANXA2 protein, humanB7 AntigensCD276 protein, humanProtein Isoforms2Ig isoformANXA2B7‐H3NSUN2RNA methylationYBX1

Identifiers

PMID39048916
PMCPMC11269050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.